MedTrace Logo

Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?

NCT02443285 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-06-20

No results posted yet for this study

Summary

Current European and most other international guidelines recommend the use of a third-generation cephalosporin as the first choice, or amoxicillin-clavulanate acid or fluoroquinolones as an alternative choice .

These recommendations are based mainly on clinical trials that were very often conducted a decade or more ago, and on the assumption that E. coli would be involved in nearly half of the cases.

The microbial etiology of SBP remains relatively constant; however, the antibiotic resistance rate especially for third-generation cephalosporins (including cefotaxime and ceftazidime), ciprofloxacin, and ofloxacin increased dramatically .

Conditions

  • Primary Bacterial Peritonitis

Interventions

DRUG

Cefotaxime

Cefotaxime 2 gram every12 hours for 5 days

DRUG

ceftriaxone

Ceftriaxone 2 gm every 24 hours for 5 days

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sherief M Abd-elsalam, lecturer · hepatology dept-Tanta

  • Hanan H Soliman, Professor · hepatology dept-Tanta

  • Walaa A Elkhalawany, lecturer · hepatology dept-Tanta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02443285 on ClinicalTrials.gov